Please wait while the formulary information is being retrieved.
Drug overview for BEPOTASTINE BESILATE (bepotastine besilate):
Generic name: BEPOTASTINE BESILATE (BEP-oh-TAS-teen)
Drug class: Ophthalmic Antiallergic Agents
Therapeutic class: Ophthalmic Agents
Bepotastine besilate is a histamine H1-receptor antagonist with mast-cell stabilizing activity.
No enhanced Uses information available for this drug.
Generic name: BEPOTASTINE BESILATE (BEP-oh-TAS-teen)
Drug class: Ophthalmic Antiallergic Agents
Therapeutic class: Ophthalmic Agents
Bepotastine besilate is a histamine H1-receptor antagonist with mast-cell stabilizing activity.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for BEPOTASTINE BESILATE (bepotastine besilate) have been approved by the FDA:
Indications:
Allergic conjunctivitis
Professional Synonyms:
Allergy eye itch
Atopic conjunctivitis
Itchy eyes due to allergies
Ocular itching due to allergies
Indications:
Allergic conjunctivitis
Professional Synonyms:
Allergy eye itch
Atopic conjunctivitis
Itchy eyes due to allergies
Ocular itching due to allergies
The following dosing information is available for BEPOTASTINE BESILATE (bepotastine besilate):
The recommended dosage of bepotastine besilate for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in adults and children 2 years of age and older is 1 drop of a 1.5% solution in the affected eye(s) twice daily.
Bepotastine besilate is applied topically to the eye as an ophthalmic solution. The manufacturer states that bepotastine besilate ophthalmic solution should not be used for the symptomatic management of contact lens-related irritation. Patients should be advised not to wear their contact lenses if their eye(s) are red.
Patients should also be advised to remove their contact lenses prior to administration of bepotastine besilate ophthalmic solution because the solution contains benzalkonium chloride, which may be absorbed by some soft contact lenses. Patients whose eyes are not red may reinsert their lenses after 10 minutes following administration of the ophthalmic solution. Bepotastine besilate is for topical ophthalmic use only.
Patients should also be advised to remove their contact lenses prior to administration of bepotastine besilate ophthalmic solution because the solution contains benzalkonium chloride, which may be absorbed by some soft contact lenses. Patients whose eyes are not red may reinsert their lenses after 10 minutes following administration of the ophthalmic solution. Bepotastine besilate is for topical ophthalmic use only.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for BEPOTASTINE BESILATE (bepotastine besilate):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for BEPOTASTINE BESILATE (bepotastine besilate):
Drug contraindication overview.
The manufacturer states that there are no known contraindications to the use of bepotastine besilate ophthalmic solution.
The manufacturer states that there are no known contraindications to the use of bepotastine besilate ophthalmic solution.
There are 0 contraindications.
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| No disease contraindications |
The following adverse reaction information is available for BEPOTASTINE BESILATE (bepotastine besilate):
Adverse reaction overview.
The most common adverse effect reported in individuals receiving bepotastine besilate ophthalmic solution is mild taste following instillation, which occurs in approximately 25% of individuals receiving the drug. Other adverse effects occurring in 2-5% of individuals receiving the drug include ocular irritation, headache, and nasopharyngitis.
The most common adverse effect reported in individuals receiving bepotastine besilate ophthalmic solution is mild taste following instillation, which occurs in approximately 25% of individuals receiving the drug. Other adverse effects occurring in 2-5% of individuals receiving the drug include ocular irritation, headache, and nasopharyngitis.
There are 1 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Tongue swelling |
There are 7 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Dysgeusia |
Headache disorder Ocular irritation Pharyngitis |
| Rare/Very Rare |
|---|
|
Edema Pruritus of skin Skin rash |
The following precautions are available for BEPOTASTINE BESILATE (bepotastine besilate):
Safety and efficacy of bepotastine besilate ophthalmic solution have not been established in pediatric patients younger than 2 years of age. Efficacy in pediatric patients younger than 10 years of age was extrapolated from clinical trials conducted in adults and pediatric patients older than 10 years of age.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Category C. (See Users Guide.)
Bepotastine besilate is distributed into milk in rats following oral administration. It is not known whether bepotastine besilate is distributed into human milk. Caution is advised if the drug is administered in nursing women.
No overall differences in efficacy or safety were observed between geriatric and younger patients.
The following prioritized warning is available for BEPOTASTINE BESILATE (bepotastine besilate):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for BEPOTASTINE BESILATE (bepotastine besilate)'s list of indications:
| Allergic conjunctivitis | |
| H10.1 | Acute atopic conjunctivitis |
| H10.10 | Acute atopic conjunctivitis, unspecified eye |
| H10.11 | Acute atopic conjunctivitis, right eye |
| H10.12 | Acute atopic conjunctivitis, left eye |
| H10.13 | Acute atopic conjunctivitis, bilateral |
| H10.44 | Vernal conjunctivitis |
| H10.45 | Other chronic allergic conjunctivitis |
| H16.26 | Vernal keratoconjunctivitis, with limbar and corneal involvement |
| H16.261 | Vernal keratoconjunctivitis, with limbar and corneal involvement, right eye |
| H16.262 | Vernal keratoconjunctivitis, with limbar and corneal involvement, left eye |
| H16.263 | Vernal keratoconjunctivitis, with limbar and corneal involvement, bilateral |
| H16.269 | Vernal keratoconjunctivitis, with limbar and corneal involvement, unspecified eye |
Formulary Reference Tool